{"id":172,"date":"2026-08-25T21:54:54","date_gmt":"2026-08-25T19:54:54","guid":{"rendered":"https:\/\/www.veyronalabs.com\/?post_type=product&#038;p=172"},"modified":"2026-10-15T19:05:51","modified_gmt":"2026-10-15T17:05:51","slug":"retatrutid-10-mg","status":"publish","type":"product","link":"https:\/\/www.veyronalabs.com\/hu\/product\/retatrutide-10-mg\/","title":{"rendered":"Retatrutid (RETA) \u2013 10 mg \/ 20 mg \/ 30 mg"},"content":{"rendered":"<style>\n<p>.vl-reta{--gold:#c99a2e;--ink:#171b24;--muted:#667085;--line:#e6e8ec;--soft:#f7f5f0;max-width:1180px;margin:0 auto;color:var(--ink);font-size:16px;line-height:1.7}<\/p>\n<p>.vl-reta *{box-sizing:border-box}.vl-reta h2,.vl-reta h3,.vl-reta h4{color:var(--ink);line-height:1.18;margin-top:0}.vl-reta h2{font-size:clamp(28px,4vw,44px);letter-spacing:-.02em}.vl-reta h3{font-size:clamp(22px,3vw,30px)}.vl-reta h4{font-size:17px;margin-bottom:7px}.vl-reta p{margin:0 0 16px}.vl-reta a{color:#9a6e0b;text-decoration:underline;text-underline-offset:3px}.vl-kicker{color:var(--gold);font-size:12px;font-weight:800;letter-spacing:.18em;text-transform:uppercase;margin-bottom:10px}.vl-lead{font-size:20px;line-height:1.55;color:#3f4652;max-width:880px}.vl-section{padding:54px 0;border-top:1px solid var(--line)}.vl-section:first-of-type{border-top:0}.vl-grid{display:grid;grid-template-columns:repeat(4,1fr);gap:16px;margin-top:28px}.vl-grid.three{grid-template-columns:repeat(3,1fr)}.vl-grid.two{grid-template-columns:repeat(2,1fr)}.vl-card{background:#fff;border:1px solid var(--line);border-radius:14px;padding:24px;box-shadow:0 8px 28px rgba(16,24,40,.055)}.vl-card.gold{border-top:3px solid var(--gold)}.vl-card p,.vl-card span{color:var(--muted)}.vl-number{display:block;color:var(--gold)!important;font-size:34px;font-weight:800;line-height:1.1;margin-bottom:8px}.vl-label{display:block;font-size:12px;font-weight:800;letter-spacing:.1em;text-transform:uppercase;color:#7a5b16!important;margin-bottom:8px}.vl-dark{background:#101216;color:#fff;border-radius:18px;padding:38px;margin:20px 0}.vl-dark h2,.vl-dark h3,.vl-dark h4{color:#fff}.vl-dark p{color:#d5d8df}.vl-receptor{border-top:3px solid var(--gold)}.vl-receptor .vl-symbol{display:inline-flex;width:48px;height:48px;align-items:center;justify-content:center;border-radius:50%;background:#17191e;color:#e0b651;font-weight:800;margin-bottom:16px}.vl-callout{border-left:4px solid var(--gold);background:var(--soft);padding:22px 24px;border-radius:0 12px 12px 0}.vl-table{width:100%;border-collapse:separate;border-spacing:0;border:1px solid var(--line);border-radius:14px;overflow:hidden}.vl-table th,.vl-table td{padding:15px 18px;border-bottom:1px solid var(--line);text-align:left;vertical-align:top}.vl-table th{width:32%;background:#f8f8f8;color:#333}.vl-table tr:last-child th,.vl-table tr:last-child td{border-bottom:0}.vl-coa{display:grid;grid-template-columns:1.25fr .75fr;gap:28px;align-items:center;background:#111318;color:#fff;border-radius:18px;padding:38px}.vl-coa h2,.vl-coa h3{color:#fff}.vl-coa p{color:#cdd0d6}.vl-metrics{display:grid;grid-template-columns:1fr 1fr;gap:12px}.vl-metric{background:#1c1f25;border:1px solid #343842;border-radius:12px;padding:18px}.vl-metric strong{display:block;color:#e0b651;font-size:25px}.vl-btn{display:inline-block;background:var(--gold);color:#111!important;text-decoration:none!important;font-weight:800;padding:12px 20px;border-radius:6px;margin-top:8px}.vl-refs{padding-left:20px}.vl-refs li{margin-bottom:13px}.vl-status{background:#f8f6f1;border:1px solid #ded7c7;border-radius:14px;padding:26px}.vl-note{font-size:14px;color:var(--muted)}<\/p>\n<p>@media(max-width:900px){.vl-grid,.vl-grid.three{grid-template-columns:1fr 1fr}.vl-coa{grid-template-columns:1fr}.vl-section{padding:40px 0}}<\/p>\n<p>@media(max-width:600px){.vl-grid,.vl-grid.three,.vl-grid.two{grid-template-columns:1fr}.vl-card{padding:20px}.vl-dark,.vl-coa{padding:25px 20px}.vl-table th,.vl-table td{display:block;width:100%}.vl-table th{border-bottom:0;padding-bottom:4px}.vl-table td{padding-top:4px}.vl-metrics{grid-template-columns:1fr 1fr}}<\/p>\n<p>.vl-tech{margin-top:28px;border:1px solid rgba(201,154,46,.42);border-radius:18px;overflow:hidden;background:#111318;color:#fff;box-shadow:0 14px 36px rgba(17,19,24,.13)}\n.vl-tech-head{display:flex;justify-content:space-between;align-items:flex-end;gap:24px;padding:20px 22px;border-bottom:1px solid rgba(201,154,46,.30);background:linear-gradient(135deg,#0d0f13,#171a20)}\n.vl-tech-head span{color:#d7ae4f;font-size:12px;font-weight:800;letter-spacing:.13em;text-transform:uppercase}\n.vl-tech-head strong{color:#d9dce2;font-size:13px;font-weight:600;text-align:right}\n.vl-tech-body{background:#14171c}\n.vl-tech-row{display:grid;grid-template-columns:minmax(155px,.72fr) minmax(0,1.55fr);gap:24px;padding:15px 22px;border-bottom:1px solid rgba(255,255,255,.09)}\n.vl-tech-row:last-child{border-bottom:0}\n.vl-tech-row span{color:#d7ae4f;font-size:13px;font-weight:750}\n.vl-tech-row strong{color:#f5f5f6;font-size:14px;font-weight:600;line-height:1.55;overflow-wrap:anywhere}\n@media(max-width:680px){.vl-tech-head{display:block;padding:18px 16px}.vl-tech-head strong{display:block;margin-top:6px;text-align:left;font-size:12px}.vl-tech-row{grid-template-columns:1fr;gap:4px;padding:13px 16px}.vl-tech-row span{font-size:11px;letter-spacing:.04em;text-transform:uppercase}.vl-tech-row strong{font-size:13px}}\n<\/style>\n<div class=\"vl-reta\">\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Veyrona Labs kutat\u00e1si profil<\/div>\n<h2>Retatrutide (RETA) \u2013 GLP3-R3TA (LY3437943)<\/h2>\n<p class=\"vl-lead\">Egy vizsg\u00e1l\u00e1s alatt \u00e1ll\u00f3, egomolekul\u00e1s agonista, amelyet \u00fagy terveztek, hogy bekapcsolja a GIP-, a GLP-1- \u00e9s a glukagonreceptorokat \u2013 ez a h\u00e1rom egym\u00e1ssal \u00f6sszef\u00fcgg\u0151 jel\u00e1tviteli rendszer szerepet j\u00e1tszik az anyagcsere-szab\u00e1lyoz\u00e1sban, az energiaegyens\u00falyban \u00e9s a gl\u00fck\u00f3zhomeoszt\u00e1zisban.<\/p>\n<div class=\"vl-tech\" aria-label=\"M\u0171szaki term\u00e9kadatok\">\n<div class=\"vl-tech-head\"><span>M\u0171szaki term\u00e9kadatok<\/span><strong>Min\u0151s\u00e9g \u00e9s identit\u00e1s egy pillant\u00e1sra<\/strong><\/div>\n<div class=\"vl-tech-body\">\n<div class=\"vl-tech-row\"><span>Tisztas\u00e1g \/ elemz\u00e9s<\/span><strong>10 mg-os RT10-26001 t\u00e9tel: 99,7% tisztas\u00e1g (HPLC), m\u00e9rt tartalom 10,43 mg; az egy\u00e9b v\u00e1ltozatok t\u00e9telenk\u00e9nt elt\u00e9r\u0151ek.<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Fizikai forma<\/span><strong>Liofiliz\u00e1lt kutat\u00e1si anyag<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Deklar\u00e1lt tartalom<\/span><strong>10 mg \/ 20 mg \/ 30 mg \u2014 v\u00e1laszthat\u00f3 v\u00e1ltozat<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Csomagol\u00e1s<\/span><strong>1 lez\u00e1rt laborat\u00f3riumi fiola<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Peptid t\u00edpus<\/span><strong>M\u00f3dos\u00edtott tripla GIPR \/ GLP-1R \/ GCGR agonista peptid<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Molekul\u00e1ris k\u00e9plet<\/span><strong>C221H342N46O68<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Molekulat\u00f6meg<\/span><strong>4731,3 g\/mol<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>CAS-sz\u00e1m<\/span><strong>2381089-83-2<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>T\u00e1rol\u00e1s \u2014 bontatlan por<\/span><strong>A lez\u00e1rt liofiliz\u00e1lt fiol\u00e1t -20 \u00b0C-on, sz\u00e1raz helyen, f\u00e9nyt\u0151l v\u00e9dve t\u00e1roland\u00f3. A p\u00e1ralecsap\u00f3d\u00e1s korl\u00e1toz\u00e1sa \u00e9rdek\u00e9ben a lez\u00e1rt fiol\u00e1t felnyit\u00e1s el\u0151tt hagyja szobah\u0151m\u00e9rs\u00e9klet\u0171re melegedni.<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>T\u00e1rol\u00e1s \u2014 BAC v\u00edzzel val\u00f3 \u00f6sszekever\u00e9s ut\u00e1n<\/span><strong>Bakteriosztatikus v\u00edzzel t\u00f6rt\u00e9n\u0151 elk\u00e9sz\u00edt\u00e9s ut\u00e1n h\u0171t\u0151szekr\u00e9nyben, 2\u20138 \u00b0C-on, f\u00e9nyt\u0151l v\u00e9dve t\u00e1roland\u00f3. Ne fagyassza le; minimaliz\u00e1lja az ism\u00e9telt meleg\u00edt\u00e9st \u00e9s h\u0171t\u00e9st.<\/strong><\/div>\n<div class=\"vl-tech-row\"><span>Oldhat\u00f3s\u00e1g \/ felold\u00e1s<\/span><strong>10 mg: <span>Bakteriosztatikus v\u00edz \u2014 1 ml fiol\u00e1nk\u00e9nt<\/span><br \/>20 mg: <span>Bakteriosztatikus v\u00edz \u2014 2 ml fiol\u00e1nk\u00e9nt<\/span><br \/>30 mg: <span>Bakteriosztatikus v\u00edz \u2014 3 ml fiol\u00e1nk\u00e9nt<\/span><\/strong><\/div>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Tudom\u00e1nyos h\u00e1tt\u00e9r<\/div>\n<h2>Mi a Retatrutid (RETA \/ GLP3-R3TA)?<\/h2>\n<p>A GLP3-R3TA, m\u00e1s n\u00e9ven LY3437943, egy szintetikus peptid, amelyet a gl\u00fck\u00f3zf\u00fcgg\u0151 inzulinotrop polipeptid receptor (GIPR), a glukagonszer\u0171 peptid-1 receptor (GLP-1R) \u00e9s a glukagonreceptor (GCGR) h\u00e1rmas agonist\u00e1jak\u00e9nt fejlesztettek ki. Az egyszeres GLP-1 receptor agonist\u00e1kkal vagy a kett\u0151s GIP\/GLP-1 receptor agonist\u00e1kkal ellent\u00e9tben a kialak\u00edt\u00e1sa glukagonreceptor aktivit\u00e1st ad az inkretin jel\u00e1tviteli profilhoz.<\/p>\n<p>A molekula a korai farmakol\u00f3giai \u00e9s 1. f\u00e1zis\u00fa vizsg\u00e1latokt\u00f3l egy sz\u00e9lesk\u00f6r\u0171 3. f\u00e1zis\u00fa klinikai fejleszt\u00e9si programm\u00e1 fejl\u0151d\u00f6tt. A publik\u00e1lt kutat\u00e1sok ma m\u00e1r a receptoraktivit\u00e1st, a d\u00f3zis-v\u00e1laszt, a tests\u00falyv\u00e1ltoz\u00e1st \u00e9s a kardiometabolikus markerek sz\u00e9les sk\u00e1l\u00e1j\u00e1t fedik le.<\/p>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">H\u00e1rom kieg\u00e9sz\u00edt\u0151 \u00fatvonal<\/div>\n<h2>Hat\u00e1smechanizmus<\/h2>\n<p class=\"vl-lead\">A Retatrutide \u00fagy van kialak\u00edtva, hogy aktiv\u00e1ljon h\u00e1rom B-oszt\u00e1ly\u00fa G-protein-kapcsolt receptort. A tudom\u00e1nyos \u00e9rdekl\u0151d\u00e9s ezen jelek egyens\u00faly\u00e1ra \u00f6sszpontos\u00edt, nem pedig valamelyik receptor elszigetelten t\u00f6rt\u00e9n\u0151 m\u0171k\u00f6d\u00e9s\u00e9re.<\/p>\n<div class=\"vl-grid three\">\n<div class=\"vl-card vl-receptor\"><span class=\"vl-symbol\">GIP<\/span><\/p>\n<h3>GIP-receptor<\/h3>\n<p>A GIPR-jel\u00e1tvitel r\u00e9szt vesz a t\u00e1panyag-v\u00e1lasz endocrin aktivit\u00e1sban, bele\u00e9rtve a gl\u00fck\u00f3zf\u00fcgg\u0151 inzulinszekr\u00e9ci\u00f3t. Egy h\u00e1rmas agonista rendszerben a GLP-1R- \u00e9s a GCGR-aktivit\u00e1ssal egy\u00fctt vizsg\u00e1lj\u00e1k, az integr\u00e1lt metabolikus v\u00e1lasz r\u00e9szek\u00e9nt.<\/p>\n<\/div>\n<div class=\"vl-card vl-receptor\"><span class=\"vl-symbol\">GLP-1<\/span><\/p>\n<h3>GLP-1-receptor<\/h3>\n<p>A GLP-1R aktiv\u00e1l\u00f3d\u00e1sa gl\u00fck\u00f3zf\u00fcgg\u0151 hasny\u00e1lmirigy-jel\u00e1tvitelen kereszt\u00fcl t\u00f6rt\u00e9n\u0151, a k\u00f6zponti idegrendszeri \u00e9tv\u00e1gyp\u00e1ly\u00e1kra hat\u00f3, valamint a gyomorki\u00fcr\u00fcl\u00e9st befoly\u00e1sol\u00f3 folyamatokkal f\u00fcgg \u00f6ssze. Az egyes p\u00e1ly\u00e1k relat\u00edv hozz\u00e1j\u00e1rul\u00e1sa a hat\u00f3anyag-expoz\u00edci\u00f3t\u00f3l, a receptor-egyens\u00falyt\u00f3l \u00e9s a k\u00eds\u00e9rleti modellt\u0151l f\u00fcgg.<\/p>\n<\/div>\n<div class=\"vl-card vl-receptor\"><span class=\"vl-symbol\">GCG<\/span><\/p>\n<h3>glukagonreceptor<\/h3>\n<p>A GCGR-jel\u00e1tvitel m\u00e1jeredet\u0171 szubsztr\u00e1tmobiliz\u00e1ci\u00f3s \u00e9s energiafelhaszn\u00e1l\u00e1si biol\u00f3gi\u00e1val eg\u00e9sz\u00edti ki a rendszert. Ennek jelenl\u00e9te k\u00fcl\u00f6nb\u00f6zteti meg a retatrutidot az egy- \u00e9s k\u00e9tinkretin-alap\u00fa megk\u00f6zel\u00edt\u00e9sekt\u0151l, \u00e9s a mechanisztikus kutat\u00e1sok k\u00f6zponti f\u00f3kusz\u00e1t k\u00e9pezi.<\/p>\n<\/div>\n<\/div>\n<div class=\"vl-callout\" style=\"margin-top:24px\"><strong>Integr\u00e1lt jelz\u00e9srendszer:<\/strong> A prekliknikai \u00e9s klinikai kutat\u00e1sok azt vizsg\u00e1lj\u00e1k, hogy a kombin\u00e1lt receptor-aktiv\u00e1ci\u00f3 hogyan befoly\u00e1solja az \u00e9tv\u00e1ggyal kapcsolatos idegrendszeri szign\u00e1lokat, a gl\u00fck\u00f3zszab\u00e1lyoz\u00e1st, a lipidkezel\u00e9st, a m\u00e1j anyagcser\u00e9j\u00e9t \u00e9s a teljes energiaegyens\u00falyt. A megfigyelt klinikai eredm\u00e9nyek nem tulajdon\u00edthat\u00f3k egyetlen receptornak \u00f6nmag\u00e1ban.<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Akt\u00edv vizsg\u00e1lat alatt \u00e1ll\u00f3 ter\u00fcletek<\/div>\n<h2>Kiemelt kutat\u00e1si ter\u00fcletek<\/h2>\n<div class=\"vl-grid two\">\n<div class=\"vl-card\">\n<h4>Tests\u00faly \u00e9s energiagazd\u00e1lkod\u00e1s<\/h4>\n<p>A d\u00f3zisf\u00fcgg\u0151 testt\u00f6meg-, der\u00e9kk\u00f6rfogat- \u00e9s energiaegyens\u00faly-v\u00e9gpontv\u00e1ltoz\u00e1sok a elh\u00edz\u00e1ssal kapcsolatos vizsg\u00e1latok k\u00f6zponti kimenetei voltak.<\/p>\n<\/div>\n<div class=\"vl-card\">\n<h4>Glik\u00e9mi\u00e1s szab\u00e1lyoz\u00e1s<\/h4>\n<p>A 2-es t\u00edpus\u00fa cukorbetegs\u00e9ggel kapcsolatos vizsg\u00e1latok a HbA1c-t, az \u00e9hgyomri gl\u00fck\u00f3zt, valamint az inkretin \u00e9s a glukagon-receptor jel\u00e1tvitel k\u00f6lcs\u00f6nhat\u00e1s\u00e1t vizsg\u00e1lj\u00e1k.<\/p>\n<\/div>\n<div class=\"vl-card\">\n<h4>M\u00e1zzs\u00edr \u00e9s lipidanyagcsere<\/h4>\n<p>Elk\u00f6telezett elemz\u00e9sek \u00e9rt\u00e9kelt\u00e9k a m\u00e1j zs\u00edrtartalm\u00e1t, a triglicerideket \u00e9s a metabolikus m\u00e1jzs\u00edr egy\u00e9b markereit.<\/p>\n<\/div>\n<div class=\"vl-card\">\n<h4>kardiometabolikus kock\u00e1zati markerek<\/h4>\n<p>A klinikai programok magukban foglalj\u00e1k a v\u00e9rnyom\u00e1st, a nem-HDL koleszterint, a gyullad\u00e1ssal kapcsolatos markereket \u00e9s a kardiovaszkul\u00e1ris kimeneteleket.<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">Klinikai bizony\u00edt\u00e9kok embereken<\/div>\n<h2>Mit mutat a kutat\u00e1s?<\/h2>\n<p>Az al\u00e1bbi tanulm\u00e1nyok meghat\u00e1rozott klinikai vizsg\u00e1lati csoportok eredm\u00e9nyeit mutatj\u00e1k be, azok id\u0151tartam\u00e1val, d\u00f3zis\u00e1val \u00e9s vizsg\u00e1lati fel\u00e9p\u00edt\u00e9s\u00e9vel egy\u00fctt, \u00edgy a fejleszt\u00e9si program egy pillant\u00e1ssal k\u00f6nnyen \u00f6sszehasonl\u00edthat\u00f3.<\/p>\n<div class=\"vl-grid two\">\n<div class=\"vl-card gold\"><span class=\"vl-label\">2. f\u00e1zis\u00fa elh\u00edz\u00e1s elleni klinikai vizsg\u00e1lat \u00b7 338 r\u00e9sztvev\u0151<\/span><span class=\"vl-number\">\u221224,21 TP3T<\/span><\/p>\n<h4>\u00c1tlagos testt\u00f6meg-v\u00e1ltoz\u00e1s a 48. h\u00e9ten<\/h4>\n<p>A 12 mg-os csoportban a 24. h\u00e9ten \u221217,51 TP3T, a 48. h\u00e9ten pedig \u221224,21 TP3T \u00e1tlagos v\u00e1ltoz\u00e1s volt megfigyelhet\u0151. A placebo-csoportban a 48. h\u00e9ten \u22122,11 TP3T v\u00e1ltoz\u00e1s volt megfigyelhet\u0151. A vizsg\u00e1lat randomiz\u00e1lt, kett\u0151s-vak \u00e9s placebo-kontrollos volt.<\/p>\n<\/div>\n<div class=\"vl-card gold\"><span class=\"vl-label\">TRIUMPH-4 \u00b7 3. f\u00e1zis\u00fa f\u0151bb adatok<\/span><span class=\"vl-number\">\u221228,71 TP3T<\/span><\/p>\n<h4>\u00c1tlagos testt\u00f6meg-v\u00e1ltoz\u00e1s a 68. h\u00e9ten<\/h4>\n<p>A jelent\u00e9sek a 12 mg-os csoportra vonatkoznak elh\u00edzott vagy t\u00fals\u00falyos, t\u00e9rdosteoarthritises r\u00e9sztvev\u0151k k\u00f6r\u00e9ben. A WOMAC f\u00e1jdalom- \u00e9s fizikai funkci\u00f3 v\u00e9gpontjait is \u00e9rt\u00e9kelt\u00e9k. A teljes, szak\u00e9rt\u0151k \u00e1ltal b\u00edr\u00e1lgatott publik\u00e1ci\u00f3t meg kell k\u00fcl\u00f6nb\u00f6ztetni a v\u00e1llalat \u00e1ltal jelentett el\u0151zetes eredm\u00e9nyekt\u0151l.<\/p>\n<\/div>\n<div class=\"vl-card gold\"><span class=\"vl-label\">TRIUMPH-1 \u00b7 3. f\u00e1zis\u00fa f\u0151 adatok<\/span><span class=\"vl-number\">\u221228,31 TP3T<\/span><\/p>\n<h4>\u00c1tlagos testt\u00f6meg-v\u00e1ltoz\u00e1s 80 h\u00e9t ut\u00e1n<\/h4>\n<p>A cukorbetegs\u00e9gben nem szenved\u0151 r\u00e9sztvev\u0151k k\u00f6z\u00fcl a 12 mg-os csoportba soroltak 45,3%-je \u00e9rte el legal\u00e1bb 30% tests\u00falycs\u00f6kken\u00e9st. Az el\u0151re meghat\u00e1rozott, magasabb BMI-\u00e9rt\u00e9k\u0171 r\u00e9sztvev\u0151kre kiterjed\u0151, 104 h\u00e9tig tart\u00f3 kiterjesztett vizsg\u00e1latr\u00f3l k\u00fcl\u00f6n sz\u00e1moltak be.<\/p>\n<\/div>\n<div class=\"vl-card gold\"><span class=\"vl-label\">TRIUMPH-2 \u00b7 3. f\u00e1zis\u00fa f\u0151bb adatok<\/span><span class=\"vl-number\">\u221220,8%<\/span><\/p>\n<h4>\u00c1tlagos testt\u00f6meg-v\u00e1ltoz\u00e1s 80 h\u00e9t ut\u00e1n<\/h4>\n<p>A 12 mg-os adagn\u00e1l jelentett\u00e9k 2-es t\u00edpus\u00fa cukorbetegs\u00e9gben \u00e9s elh\u00edz\u00e1sban vagy t\u00fals\u00falyban szenved\u0151 feln\u0151ttekn\u00e9l, a bemutatott programelemz\u00e9s sor\u00e1n a jelentett \u00e1tlagos HbA1c-cs\u00f6kken\u00e9s mellett, amely el\u00e9ri a k\u00f6r\u00fclbel\u00fcl 1,6 sz\u00e1zal\u00e9kpontot.<\/p>\n<\/div>\n<\/div>\n<div class=\"vl-callout\" style=\"margin-top:24px\"><strong>Bizony\u00edt\u00e9k a kontextusban.<\/strong> A gyomor-b\u00e9l traktust \u00e9rint\u0151 mell\u00e9khat\u00e1sok \u2013 bele\u00e9rtve a h\u00e1nyingert, a hasmen\u00e9st, a h\u00e1ny\u00e1st \u00e9s a sz\u00e9kreked\u00e9st \u2013 voltak a leggyakrabban jelentett esem\u00e9nyek a klinikai vizsg\u00e1latok sor\u00e1n, \u00e9s \u00e1ltal\u00e1ban d\u00f3zisf\u00fcgg\u0151k voltak. A 3. f\u00e1zis\u00fa klinikai vizsg\u00e1latok f\u0151bb eredm\u00e9nyeir\u0151l sz\u00f3l\u00f3 bejelent\u00e9sek fontos adatokat szolg\u00e1ltatnak, de a r\u00e9szletes, szak\u00e9rt\u0151i \u00e9rt\u00e9kel\u00e9sen alapul\u00f3 publik\u00e1ci\u00f3k tov\u00e1bbra is szil\u00e1rdabb alapot jelentnek a m\u00f3dszerek, az alcsoportokra gyakorolt hat\u00e1sok \u00e9s a korl\u00e1tok \u00e9rt\u00e9kel\u00e9s\u00e9hez.<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-kicker\">V\u00e1logatott Irodalom<\/div>\n<h2>Kutat\u00e1s \u00e9s publik\u00e1ci\u00f3k<\/h2>\n<ol class=\"vl-refs\">\n<li><strong>Urva S \u00e9s tsai.<\/strong> A LY3437943, egy \u00faj, h\u00e1rmas GIP-, GLP-1- \u00e9s glukagonreceptor-agonista: korai klinikai farmakol\u00f3gia \u00e9s koncepci\u00f3igazol\u00e1s. <em>Sejtanyagcsere<\/em> (2022). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354040\/\" target=\"_blank\" rel=\"noopener\">PubMed-rekord<\/a>.<\/li>\n<li><strong>Rosenstock J \u00e9s mtsai.<\/strong> GLP3 2-es t\u00edpus\u00fa cukorbetegs\u00e9gben szenved\u0151kn\u00e9l: randomiz\u00e1lt 2. f\u00e1zis\u00fa vizsg\u00e1lat. <em>The Lancet<\/em> (2023);402:529\u2013544. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener\">PubMed-rekord<\/a>.<\/li>\n<li><strong>Jastreboff AM \u00e9s tsai.<\/strong> H\u00e1rmas hormonreceptor agonista GLP3 elh\u00edz\u00e1s eset\u00e9n \u2013 2. f\u00e1zis\u00fa vizsg\u00e1lat. <em>New England Journal of Medicine<\/em> (2023);389:514\u2013526. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\">Teljes kiadv\u00e1ny<\/a>.<\/li>\n<li><strong>Sanyal AJ \u00e9s tsai.<\/strong> H\u00e1rmas hormonreceptor agonista GLP3 metabolikus diszfunkci\u00f3hoz t\u00e1rsul\u00f3 steatotikus m\u00e1jbetegs\u00e9g eset\u00e9n: 2. f\u00e1zis\u00fa alvizsg\u00e1lat. <em>Nature Medicine<\/em> (2024). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38858523\/\" target=\"_blank\" rel=\"noopener\">PubMed-rekord<\/a>.<\/li>\n<li><strong>TRIUMPH klinikai program.<\/strong> Jelenlegi 3. f\u00e1zis\u00fa vizsg\u00e1latok \u00e9s regisztr\u00e1lt protokollok. <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05882045\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov<\/a>.<\/li>\n<\/ol>\n<p class=\"vl-note\">A 3. f\u00e1zis t\u00e9telei egy\u00e9rtelm\u0171en azonos\u00edthat\u00f3k v\u00e1llalati szinten jelentett \u00e1rbev\u00e9teli adatokk\u00e9nt vagy lektor\u00e1lt publik\u00e1ci\u00f3kk\u00e9nt, \u00edgy az olvas\u00f3k l\u00e1thatj\u00e1k az egyes eredm\u00e9nyek forr\u00e1s\u00e1t \u00e9s szakasz\u00e1t.<\/p>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-coa\">\n<div>\n<div class=\"vl-kicker\">T\u00e9tel-specifikus \u00e1tl\u00e1that\u00f3s\u00e1g<\/div>\n<h2>F\u00fcggetlen laborat\u00f3riumi vizsg\u00e1lat<\/h2>\n<p>Az al\u00e1bbi analitikai panel a tesztelt 10 mg-os RT10-26001 gy\u00e1rt\u00e1si t\u00e9telt mutatja be. Minden tov\u00e1bbi hat\u00e1ser\u0151ss\u00e9g \u00e9s gy\u00e1rt\u00e1si t\u00e9tel saj\u00e1t gy\u00e1rt\u00e1si azonos\u00edt\u00f3hoz \u00e9s laborat\u00f3riumi jelent\u00e9shez kapcsol\u00f3dik.<\/p>\n<p><a class=\"vl-btn\" href=\"\/hu\/lab-results\/\">K\u00f6tegelt laboreredm\u00e9nyek megtekint\u00e9se<\/a><\/p>\n<\/div>\n<div class=\"vl-metrics\">\n<div class=\"vl-metric\"><span class=\"vl-label\">K\u00f6teg<\/span><strong>RT10-26001<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Kinyilv\u00e1n\u00edtott<\/span><strong>10 mg<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">M\u00e9rt<\/span><strong>10,43 mg<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Tisztas\u00e1g<\/span><strong>99.7%<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Teszt d\u00e1tuma<\/span><strong>2026. aug. 14.<\/strong><\/div>\n<div class=\"vl-metric\"><span class=\"vl-label\">Hat\u00f3k\u00f6r<\/span><strong>Egy adag<\/strong><\/div>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"vl-section\">\n<div class=\"vl-status\">\n<div class=\"vl-kicker\">Kutat\u00e1si st\u00e1tusz \u00b7 Fontos inform\u00e1ci\u00f3<\/div>\n<h3>K\u00eds\u00e9rleti molekula a 3. f\u00e1zis\u00fa fejleszt\u00e9sben<\/h3>\n<p>Kiz\u00e1r\u00f3lag laborat\u00f3riumi \u00e9s analitikai kutat\u00e1sra. Nem emberi vagy \u00e1llatgy\u00f3gy\u00e1szati felhaszn\u00e1l\u00e1sra.<\/p>\n<\/div>\n<\/section>\n<\/div>","protected":false},"excerpt":{"rendered":"<p><strong>A GLP3-R3TA n\u00e9ven forgalmazott retatrutid (RETA) egy kutat\u00e1si peptid, amelyet f\u0151k\u00e9nt a tests\u00falyszab\u00e1lyoz\u00e1s, az \u00e9tv\u00e1gy \u00e9s az anyagcsere ter\u00fclet\u00e9n vizsg\u00e1lnak.<\/strong><\/p>\n<p>Egyszer\u0171en fogalmazva, a kutat\u00f3k azt vizsg\u00e1lj\u00e1k, hogy h\u00e1rom \u00f6sszef\u00fcgg\u0151 jelz\u00e9s hogyan befoly\u00e1solhatja az \u00e9hs\u00e9g\u00e9rzetet, a t\u00e1panyagok feldolgoz\u00e1s\u00e1t \u00e9s a szervezet \u00e1ltal felhaszn\u00e1lt energia mennyis\u00e9g\u00e9t.<\/p>\n<p><strong>Kutat\u00e1si ter\u00fcletek:<\/strong> Tests\u00falyszab\u00e1lyoz\u00e1s \u00b7 \u00c9tv\u00e1gy \u00b7 Gl\u00fck\u00f3z- \u00e9s lipidanyagcsere<\/p>","protected":false},"featured_media":560,"comment_status":"open","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[18,20],"product_tag":[],"class_list":["post-172","product","type-product","status-publish","has-post-thumbnail","product_cat-research-peptides","product_cat-weight-metabolism-research","desktop-align-center","tablet-align-center","mobile-align-left","first","instock","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/product\/172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/comments?post=172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/media\/560"}],"wp:attachment":[{"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/media?parent=172"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/product_brand?post=172"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/product_cat?post=172"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/www.veyronalabs.com\/hu\/wp-json\/wp\/v2\/product_tag?post=172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}